Search
TRC093
go.drugbank.com/drugs/DB06356InvestigationalTRC093 is a recombinant humanized IgG1k monoclonal antibody.
DTS-201
go.drugbank.com/drugs/DB06071Experimentalsolid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which express high levels of CD-10* or TOP** peptidases, such as
Epicept NP-1
go.drugbank.com/drugs/DB05492InvestigationalEpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used antidepressant) and ketamine (an NMDA antagonist that is used as an anesthetic).
OSI-7836
go.drugbank.com/drugs/DB05837ExperimentalOSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine.
PI-0824
go.drugbank.com/drugs/DB05516InvestigationalPeptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824.
MVA-BN-brachyury-TRICOM vaccine
go.drugbank.com/drugs/DB17424Investigational[L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.
Umbilical Cord Blood Hematopoietic Stem Cells
go.drugbank.com/drugs/DB15723InvestigationalBecause HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels
WX-UK1
go.drugbank.com/drugs/DB05476InvestigationalIndependent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas.
Tunicamycin
go.drugbank.com/drugs/DB13172ExperimentalIt is used as an experimental tool to induce unfolded protein response. Tunicamycin is produced by Streptomyces clavuligerus and Streptomyces lysosuperficus bacteria along with several other species.
Etesevimab
go.drugbank.com/drugs/DB15897InvestigationalEtesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.